The transcription factor retinoid-related orphan receptor gamma t (RORgt) has emerged as an exciting target for inflammatory diseases. Xiao et al. (2014) show that a new class of RORgt antagonists can inhibit the inflammatory function of T helper 17 cells without altering RORgt occupancy on its target genes.
The transcription factor retinoid-related orphan receptor gamma t (RORgt) has emerged as an exciting target for inflammatory diseases. Xiao et al. (2014) show that a new class of RORgt antagonists can inhibit the inflammatory function of T helper 17 cells without altering RORgt occupancy on its target genes.
The discovery of pathogenic T helper 17 (Th17) cells nearly a decade ago (Ivanov et al., 2006) has led to the development of targeting strategies to inhibit inflammatory T cell activities for the treatment of autoimmune disorders. At the core of these therapeutic approaches is antibody-mediated neutralization of interleukin-23 (IL-23) and IL-17, which is showing encouraging results for treatment of psoriasis, multiple sclerosis, Crohn's disease, and ankylosing spondylitis (Patel et al., 2013 , Sandborn et al., 2012 . These clinical proof-of-concept studies underscore the advantage and effectiveness of suppressing retinoid-related orphan receptor gamma t (RORgt) + IL-23R + Th17 cells. Additional approaches include (1) blockade of IL-23R signaling through the suppression of JAK2-and TYK2-dependent STAT3 activation and (2) direct inhibition of RORgt-the nuclear hormone receptor (NHR) transcription factor that controls Th17 cell development and function. In the current issue of Immunity, Xiao et al. (2014) describe the screening and validation of small-molecule inhibitors of RORg. What distinguishes this study from others is the combined use of a large-scale pharmaceutical discovery platform with innovative genome-wide analysis of RORgt target genes in Th17 cells. Aside from its potential clinical value, the advantage of small-molecule inhibitors of a NHR transcription factor is the opportunity to dissect the molecular mechanisms of RORgt regulation and the RORgt-dependent transcriptional landscape not only in Th17 cells but also in other RORgt-expressing cell types. Screening through a library of ($2 million) small-molecule compounds, Xiao et al. (2014) identified TMP778, TMP920, and GSK805, which bound to and inhibited the RORg ligand-binding domain (LBD) from interacting with cofactor peptide steroid receptor coactivator 1 (SRC-1) in a fluorescence resonance energy transfer assay. These compounds were highly selective for RORg, and importantly, the inhibitory effect of the compounds on RORgt was confirmed through the suppression of effector cytokines from Th17 cells. The compounds also inhibited two different RORgt-dependent models of autoimmunity in vivo: experimental autoimmune encephalomyelitis and imiquimod-induced skin inflammation (Skepner et al., 2014) . Treatment not only delayed the onset of disease but also reduced the severity of disease progression in both models. These results support the identification of compounds that not only bind to RORgt but also effectively inhibit RORgt function both in vitro and in vivo.
RORgt belongs to a family of NHR transcriptional factors that are composed of protein structures with a separate DNA-binding domain (DBD) and LBD. The DBD imparts gene-targeting specificity, whereas the LBD serves as control switches for transcription regulatory functions (Huh and Littman, 2012) . Over the past few years, the search for RORgt inhibitors has yielded molecules that engage the LBD, induce conformational changes, and prevent recruitment of coactivators (e.g., SRCs). Examples include diverse chemical structural classes of compounds, including digoxin, SR1001, and ursolic acid (Huh et al., 2011 , Solt et al., 2011 , Xu et al., 2011 . Digoxin and SR1001 bind the LBD of RORg and inhibit the recruitment of coactivator SRCs by disrupting helix H12 of the RORgt ligand-binding pocket. Ursolic acid also interrupts RORg LBD interaction with SRC-1, and all of the compounds effectively inhibit expression of genes that are preferentially expressed in Th17 cells. However, until now, the direct effects of RORgt inhibitors on RORgt-dependent transcription programs have not been analyzed in detail.
By taking the innovative approach of pairing chromatin immunoprecipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq) data, Xiao et al. (2014) were able to gain broad insights into the direct transcriptional effects of the RORgt inhibitors on the basis of changes in RORgt occupancy on its target genes, as well as global transcriptional modulations. As expected, many of the genes that were suppressed after treatment with the inhibitors were Th17-cell-specific genes, such as Il17a and Il23r, confirming the strong inhibition of Th17 cell differentiation and IL-17 production. However, similar to Rorc À/À cells, RORgt-inhibited cells also led to the induction of signature genes from other CD4 + T helper cell lineages, such as Il4 and Tbx21. As observed for many other transcriptional regulators, RORgt functions as both an activator and a repressor of a wide range of target genes, and the effect of the inhibitors reveals an important function of RORgt in positively regulating the transcriptional signature of Th17 cells while suppressing those of other T helper cell lineages.
How do the inhibitors suppress the activity of RORgt? Is it simply by interrupting RORgt from binding its target genes, or is it by disrupting RORgt interaction with other transcription factors or coactivators? The answer proved to be both, but interestingly, it was specific to the compound itself. Xiao et al. (2014) compared compound-induced changes in RORgt gene occupancy by using genome-wide ChIP-seq, and surprisingly, the data revealed remarkable insights for the mechanism of action between the different RORgt inhibitors (Figure 1) . Whereas compound TMP920 clearly abrogated RORg occupancy of target sequences, RORg binding activities were preserved when cells were treated with TMP778 or GSK805. An unanticipated effect of TMP778 or GSK805 was that these compounds appeared to stabilize RORgt occupancy in certain genomic loci, and interestingly, treatment with either compound led to RORgt occupancy in new binding sites normally not seen in Th17 cells. A region of particular interest was the binding of RORgt to Gata3 when cells were treated with TMP778 or GSK805. These compounds induced an increase in both Gata3 mRNA and protein expression. In light of this interesting observation, additional unanswered questions arise. How do the compounds alter RORgt DNA binding, and do the additional RORgt occupancy sites contribute to the suppressed Th17 cell phenotype? It is possible that transactivation of Gata3 by RORgt participates in the inhibition of Th17 cell signature genes in cells treated with TMP778 or GSK805, perhaps through the induction of GATA3 target genes (Figure 1 ). Additional studies analyzing the effect of the compounds on RORgt interaction with coactivators and corepressors through a proteomics approach might further shed valuable insights into the molecular mechanisms of RORgt inhibition.
The strategic value of analyzing the transcriptional profile in conjunction with RORgt target-gene occupancy is the unprecedented glimpse into the potential diversity in the inhibitory mechanisms of RORg small-molecule antagonists. Although the global downstream effects after treatment with a range of compounds might appear similar, the data presented clearly show that the actual molecular mechanism can be quite diverse. The data highlight two important points: (1) (Bottom) In contrast to treatment with TMP920, treatment with TMP778 preserves RORgt occupancy on IL17a; however, IL17a transcription is inhibited. TMP778 bound to RORgt allows occupancy at additional target genes, including Gata3. Whether the suppression of Il17a is through the inhibition of RORgt interaction with coregulatory proteins or through indirect suppression from Gata3 transactivation and GATA3-induced proteins such as IL-4 and downstream STAT6 signaling remains to be determined.
